Inmode Ltd. Stock Price, News & Analysis

InMode Ltd. (Nasdaq: INMD) reported strong financial results for Q4 and FY 2021, with quarterly revenues reaching a record $110.5 million, a 47% increase year-over-year. The company achieved a GAAP net income of $52.7 million for Q4, and $165 million for the full year, compared to $75 million in 2020. Full year revenues totaled $357.6 million, a 73% increase. The company expects revenues for 2022 in the range of $415-$425 million with non-GAAP earnings per diluted share between $2.06 and $2.11. InMode continues to expand internationally and maintain healthy gross margins of 85%.

InMode Ltd. (Nasdaq: INMD) announced its anticipated financial results for the fourth quarter and full year 2021, revealing record revenues. The company expects fourth quarter revenue between $109.5M and $110M, and full year revenue of $356.5M to $357M, surpassing earlier guidance of $343M to $347M. Non-GAAP earnings per diluted share are forecasted at $0.61 for Q4 and $2.02 to $2.03 for the full year. Looking ahead, InMode projects 2022 revenues between $415M and $425M.

InMode Ltd. (Nasdaq: INMD), a global leader in innovative medical technologies, will present at the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 9:15 am EST. CEO Moshe Mizrahy and CFO Yair Malca will lead the presentation, which will be webcast live and archived for 90 days. Management will also offer one-on-one virtual meetings during the event. InMode specializes in minimally invasive radio-frequency technologies for various medical fields, including plastic surgery and dermatology.

InMode Ltd. (Nasdaq: INMD) announced participation in three virtual investor conferences. CEO Moshe Mizrahy and CFO Yair Malca will present at the Stifel 2021 Healthcare Conference on November 16 at 9:20 PM EST, the Hidden Gem Conference on November 17 at 11:15 AM EST, and the Canaccord Virtual MedTech Forum on November 18 at 1:30 PM EST. Webcasts will be available for the Stifel and Canaccord events. Investors can schedule one-on-one virtual meetings during these conferences.

InMode Ltd. (Nasdaq: INMD) reported record revenues of $94.2 million for Q3 2021, a 58% increase from Q3 2020. The company's GAAP net income reached $44.7 million, resulting in a GAAP diluted EPS of $0.52, up from $0.28 a year prior. Non-GAAP net income was $47.9 million, with an EPS of $0.55. The company has a total cash position of $387.4 million as of September 30, 2021. Looking ahead, InMode projects 2021 revenues between $343 million and $347 million.

InMode Ltd. (NASDAQ: INMD) announced expectations for record revenue for Q3 2021, projecting between $93.5M and $94M. The company also anticipates Non-GAAP earnings per diluted share to be in the range of $0.53 to $0.54, reflecting a 2-for-1 stock split effective September 30, 2021. Full-year revenue guidance has been raised to $343M - $347M with a Non-GAAP gross margin of 84% - 86%. A conference call to discuss results will take place on October 26, 2021.

InMode Ltd. (Nasdaq: INMD) has announced a two-for-one (2:1) share split, effective September 30, 2021, with a record date of September 27, 2021. Every share held by shareholders on the record date will automatically convert into two shares, impacting all shareholders uniformly without affecting their ownership percentage. The share split was approved by the board of directors on September 14, 2021. This move aims to enhance the liquidity of the shares and make them more accessible to investors.

InMode Ltd. (Nasdaq: INMD), a leader in innovative medical technologies, will participate in two upcoming virtual conferences. On September 14, CEO Moshe Mizrahy and CFO Yair Malca will present at the Baird Global Healthcare Conference at 4:20 PM ET. Additionally, they will participate in the Citi Small-Mid Cap Growth Conference on September 17, with opportunities for one-on-one meetings. Access to the conference webcasts can be found here.

InMode Ltd. (Nasdaq: INMD) has launched the EvolveX platform featuring Transform technology, designed for hands-free, non-invasive body transformation with zero downtime. The platform meets rising post-lockdown demand for non-surgical treatments, offering a unique all-in-one solution that remodels skin, treats fat, and sculpts muscles. EvolveX’s innovative features allow physicians to customize treatments addressing specific patient needs, promising consistent results. CEO Moshe Mizrahy emphasized the growing demand for such solutions, backed by InMode's strong R&D pipeline.